The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Aerie Pharmaceuticals, Inc. COM 00771V108 23,678 1,345,313 SH   SOLE   1,345,313 0 0
Aimmune Therapeutics, Inc. COM 00900T107 2,543 235,020 SH   SOLE   235,020 0 0
Akari Therapeutics, PLC SPONSORED ADR 00972G108 2,659 197,072 SH   SOLE   197,072 0 0
Alder BioPharmaceuticals, Inc. COM 014339105 39,957 1,600,183 SH   SOLE   1,600,183 0 0
Ardelyx, Inc. COM 039697107 5,251 601,485 SH   SOLE   601,485 0 0
Avexis, Inc. COM 05366U100 3,618 95,173 SH   SOLE   95,173 0 0
Bellicum Pharmaceuticals, Inc. COM 079481107 2,670 205,990 SH   SOLE   205,990 0 0
BioDelivery Sciences International, Inc. COM 09060J106 166 70,177 SH   SOLE   70,177 0 0
Epizyme, Inc. COM 29428V104 5,241 511,777 SH   SOLE   511,777 0 0
Global Blood Therapeutics, Inc. COM 37890U108 11,452 690,269 SH   SOLE   690,269 0 0
Intellia Therapeutics, Inc. COM 45826J105 16,305 763,688 SH   SOLE   763,688 0 0
Lipocine Inc. COM 53630X104 920 302,640 SH   SOLE   302,640 0 0
NanoString Technologies, Inc. COM 63009R109 895 71,000 SH   SOLE   71,000 0 0
NeuroDerm Ltd. ORD SHS M74231107 3,274 201,469 SH   SOLE   201,469 0 0
Orexigen Therapeutics, Inc. COM 686164104 1,093 2,542,575 SH   SOLE   2,542,575 0 0
Syros Pharmaceuticals, Inc. COM 87184Q107 2,723 150,000 SH   SOLE   150,000 0 0
WAVE Life Sciences Ltd. SHS Y95308105 20,071 970,104 SH   SOLE   970,104 0 0
Zafgen, Inc. COM 98885E103 3,220 537,495 SH   SOLE   537,495 0 0